Near-site monitoring of the antiplatelet drug abciximab using the hemodyne analyzer and modified thrombelastograph

This publication has 25 references indexed in Scilit:

• Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization
  Journal of the American College of Cardiology, 1997
• Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization
  New England Journal of Medicine, 1997
• Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study
  The Lancet, 1997
• A Modified Thromboelastographic Method for Monitoring c7E3 Fab in Heparinized Patients
  Anesthesia & Analgesia, 1997
• Role of Platelets in Restenosis After Percutaneous Coronary Revascularization
  Journal of the American College of Cardiology, 1996
• Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Integrin in Patients Undergoing Percutaneous Coronary Intervention
  Circulation, 1995
• Fibrin structure and concentration alter clot elastic modulus but do not alter platelet mediated force development
  Blood Coagulation & Fibrinolysis, 1995
• Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery
  The American Journal of Cardiology, 1994
• Measurement of Platelet-Mediated Force Development During Plasma Clot Formation
  The Lancet Healthy Longevity, 1991
• A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.
  Journal of Clinical Investigation, 1983